ReviewPulmonary therapy2026
Advanced Bronchoscopic Approaches to Peripheral Pulmonary Lesions: a Narrative Review of Current and Emerging Techniques.
Review in Pulmonary therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral pulmonary lesions (PPLs), defined by their location in the outer one-third of the lung, are expected to be identified with increasing frequency following the widespread adoption of lung cancer screening. The majority of PPLs will have a benign aetiology; however, obtaining tissue to exclude malignancy can be challenging, leading to high rates of benign surgical resections or prolonged surveillance imaging. Over the last two decades, there has been rapid advancement in bronchoscopic technologies, with the adoption of radial probe endobronchial ultrasound (RP-EBUS), ultrathin bronchoscopes, electromagnetic navigation bronchoscopy (ENB), virtual bronchoscopic navigation (VBN) and robotic assisted bronchoscopy (RAB). These technologies provide access to lesions that are inaccessible by conventional bronchoscopic approaches, with diagnostic yields comparable to those of CT-guided transthoracic needle biopsy (TTNB). Whilst these advanced technologies offer a lower risk of complications than CT-guided TTNB, they are significantly more expensive. In addition, advances in biopsy techniques, such as transbronchial cryobiopsy, have further enhanced the diagnostic yield for PPLs.Recent data supports the potential for a one-stop 'diagnose and treat' approach, where advanced bronchoscopic platforms are combined with thoracic surgery and rapid onsite evaluation. This offers the potential to locate and diagnose nodules prior to potential resection, thereby reducing benign resections and shortening the diagnostic pathway. The therapeutic potential of these advanced bronchoscopic platforms is an active area of research, with the potential to deliver thermal ablation therapies and intralesional brachytherapy and chemotherapy agents. This narrative review summarises the current evidence base of this rapidly evolving field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.